TearLab Corp  

(Public, NASDAQ:TEAR)   Watch this stock  
Find more results for TEAR
4.63
-0.35 (-7.03%)
Apr 17 - Close
NASDAQ real-time data - Disclaimer
Currency in USD
Range 4.59 - 5.05
52 week 4.59 - 15.18
Open 4.95
Vol / Avg. 869,984.00/370,637.00
Mkt cap 155.41M
P/E     -
Div/yield     -
EPS -0.92
Shares 33.57M
Beta 2.55
Inst. own 76%
May 8, 2014
Q1 2014 TearLab Corp Earnings Conference Call - 4:30PM EDT - Add to calendar
May 8, 2014
Q1 2014 TearLab Corp Earnings Release - 4:00PM EDT - Add to calendar
Mar 20, 2014
TearLab Corp at Stephens 1-on-1 West Coast Conference
Mar 19, 2014
TearLab Corp at Lazard MedTech, Diagnostics & Healthcare IT Snowbird Conference
Mar 13, 2014
Q4 2013 TearLab Corp Earnings Conference Call
Mar 13, 2014
Q4 2013 TearLab Corp Earnings Release
Mar 10, 2014
TearLab Corp at ROTH Conference
More events from DailyFinance »    

Key stats and ratios

Q4 (Dec '13) 2013
Net profit margin -93.58% -197.95%
Operating margin -124.04% -121.37%
EBITD margin - -108.62%
Return on average assets -32.21% -78.25%
Return on average equity -40.49% -103.15%
Employees 101 -
CDP Score - -

Address

Suite 200, 7360 Carroll Rd
SAN DIEGO, CA 92121
United States - Map
+1-858-4556006 (Phone)
+1-858-8120540 (Fax)

Website links

External links

Analyst Estimates - MarketWatch
SEC Filings - EDGAR Online
Major Holders - MSN Money

Description

TearLab Corp. is an in-vitro diagnostic company. The Company is commercializing a tear testing platform, the TearLab Osmolarity System that enables eye care practitioners to test for sensitive and specific biomarkers using nanoliters of tear film at the point-of-care. The Company's first product measures tear film osmolarity for the diagnosis of Dry Eye Disease (DED). TearLab Research, Inc., its wholly owned subsidiary, develops technologies to enable eye care practitioners to test a range of biomarkers (chemistries, metabolites (i.e. glucose), genes and proteins) at the point-of-care. Commercializing that tear testing platform is the focus of the Company's business. Its TearLab Osmolarity System, enables the measurement of tear osmolarity in the doctor's office. In March 2014, the Company acquired assets of the OcuHub business unit from AOAExcel, Inc.

Officers and directors

Elias Vamvakas Chairman of the Board, Chief Executive Officer
Age: 54
Bio & Compensation  - Reuters
Trading Activity - Yahoo Finance
Joseph Jensen President, Chief Operating Officer
Bio & Compensation  - Reuters
Robert Alan Walder Vice President - Operations
Age: 60
Bio & Compensation  - Reuters
Michael Berg Vice President - Regulatory
Bio & Compensation  - Reuters
Anthony E. Altig Independent Director
Age: 57
Bio & Compensation  - Reuters
Thomas N. Davidson Jr. Independent Director
Age: 53
Bio & Compensation  - Reuters
Adrienne L. Graves Ph.D. Independent Director
Age: 59
Bio & Compensation  - Reuters
Paul M. Karpecki Independent Director
Age: 45
Bio & Compensation  - Reuters
Richard L. Lindstrom M.D. Independent Director
Age: 65
Bio & Compensation  - Reuters